Accelerate Diagnostics, Inc. (AXDX)
$0.7241
Rating:
Recommendation:
Buy
| Symbol | AXDX |
|---|---|
| Price | $0.7241 |
| Beta | 1.101 |
| Volume Avg. | 0.28M |
| Market Cap | 71.758M |
| Shares () | - |
| 52 Week Range | 0.46-3.74 |
| 1y Target Est | - |
| DCF Unlevered | AXDX DCF -> | |
|---|---|---|
| DCF Levered | AXDX LDCF -> | |
| ROE | 172.35% | Strong Buy |
| ROA | -92.95% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -874.19% | Strong Sell |
| P/E | - | |
| P/B | -6.43 | Strong Sell |
Latest AXDX news
About
Download (Excel)Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.